Filtered By:
Education: Study
Management: Food and Drug Administration (FDA)

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 209 results found since Jan 2013.

Re-evaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK): Protocol for an Open-Label, Single-Arm, Multicenter Phase IV Trial for the Treatment of Acute Ischemic Stroke in Chinese Patients
AbstractAcute ischemic stroke (AIS) is a major medical challenge in China. Thrombolytic drugs recommended for the treatment of AIS usually have a narrow time window. Human urinary kallidinogenase (HUK) was approved by the China Food and Drug Administration (CFDA) in 2005 for the treatment of mild to moderate AIS, and it is thus widely used in China. However, large-scale clinical study data for a more complete understanding of various aspects of its safety and efficacy characteristics are still unavailable. The ongoing Reevaluate the Efficacy and Safety of Human Urinary Kallidinogenase (RESK) trial is designed to reevaluate...
Source: Translational Stroke Research - March 5, 2017 Category: Neurology Source Type: research

Study Of Brain Cooling And Clot-Busting Drug Therapy For Stroke Receives FDA OK To Expand
An international multicenter clinical trial led by a Cedars-Sinai neurologist on the combination of brain cooling and "clot-busting" drug therapy after stroke has received Food and Drug Administration approval to expand from 50 patients to 400. � "This approval is highly significant because, after reviewing our initial safety data, the Food and Drug Administration approved us to include more patients in our study," said Patrick D. Lyden, MD, chair of the Department of Neurology at Cedars-Sinai Medical Center and the study's overall principal investigator...
Source: Health News from Medical News Today - February 8, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

1H NMR-Based Metabolomics Reveals Refined-Huang-Lian-Jie-Du-Decoction (BBG) as a Potential Ischemic Stroke Treatment Drug With Efficacy and a Favorable Therapeutic Window
This study was carried out in accordance with the recommendations of Animal Ethics Committee of China Pharmaceutical University. The protocol was approved by Animal Ethics Committee of China Pharmaceutical University. Author Contributions JW, MY, and LK conceived the experiments and helped to coordinate support and funding. XF performed the research and drafted the manuscript. SL, YL, and DX participated in the experiments. JW analyzed the data and edited the paper. All authors read and approved the final manuscript. Conflict of Interest Statement The authors declare that the research was conducted in the absence of an...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Researcher Studies Statins for Stroke Therapy
Stacy Pigott A $2.8 million grant may help develop an improved therapeutic treatment for acute ischemic stroke patients to let them recover faster with fewer long-term complications. The protocol hinges on effectively delivering statins to the brain, where their neuroprotective properties can help save tissue damaged by stroke. Aug. 7, 2020 University of Arizona Health Sciencesnhg-PATRICK-RONALDSON_DSC6492-web.jpg Patrick Ronaldson (right), associate professor in the College of Medicine – Tucson's Department of Pharmacology, and doctoral students Erica Williams and Robert Betterton discuss their latest researc...
Source: The University of Arizona: Health - August 6, 2020 Category: Universities & Medical Training Authors: mittank Source Type: research

Trial of a prehospital intervention with traditional Chinese medicine for acute stroke (TRACE): Protocol for a mixed-methods research study
Discussion: The results of the TRACE study will provide preliminary evidence for the relationship between XNJI used within 24 h of onset and the presence of END on the third day after stroke onset; it will aid in improving the current knowledge regarding the early use of XNJI for stroke first aid.Clinical Trial Registration:clinicaltrials.gov, identifier NCT04275349
Source: Frontiers in Pharmacology - August 29, 2022 Category: Drugs & Pharmacology Source Type: research

The Left Atrial Appendage: Target for Stroke Reduction in Atrial Fibrillation.
Abstract A patient with atrial fibrillation (AF) has a greater than 5% annual risk of major stroke, a 5-fold increase compared to the general population. While anticoagulation remains the standard stroke prevention strategy, the nature of lifelong anticoagulation inevitably carries an increased risk of bleeding, increased stroke during periods of interruption, increased cost, and significant lifestyle modification. Many patients with atrial fibrillation have had their left atrial appendage (LAA) ligated or excised by surgeons during cardiac surgery, a decision based largely on intuition and with no clear evidence ...
Source: Methodist DeBakey Cardiovascular Journal - April 1, 2015 Category: Cardiology Authors: Ramlawi B, Abu Saleh WK, Edgerton J Tags: Methodist Debakey Cardiovasc J Source Type: research

Dl-3-n-Butylphthalide (NBP) ：A Promising Therapeutic Agent for Ischemic Stroke.
Dl-3-n-Butylphthalide (NBP)：A Promising Therapeutic Agent for Ischemic Stroke. CNS Neurol Disord Drug Targets. 2018 Jun 12;: Authors: Wang S, Ma F, Huang LJ, Zhang Y, Peng YC, Xing CH, Feng YP, Wang XL, Peng Y Abstract Stroke is a leading cause of morbidity and mortality in both developed and developing countries all over the world. The only drug for ischemic stroke approved by FDA is recombinant tissue plasminogen activator (rtPA). However, only 2-5% stroke patients receive rtPAs treatment due to its strict therapeutic time window. As ischemic stroke is a complex disease involving in multiple mecha...
Source: CNS and Neurological Disorders Drug Targets - June 12, 2018 Category: Drugs & Pharmacology Authors: Wang S, Ma F, Huang LJ, Zhang Y, Peng YC, Xing CH, Feng YP, Wang XL, Peng Y Tags: CNS Neurol Disord Drug Targets Source Type: research

Nerve stimulation could provide new treatment option for most common type of stroke
Research led by a UCLA scientist found that a new nerve stimulation therapy to increase blood flow could help patients with the most common type of stroke up to 24 hours after onset.A study of 1,000 patients found evidence that the technique, called active nerve cell cluster stimulation, reduced the patients ’ degree of disability three months after they suffered an acute cortical ischemic stroke, which affects the surface of the brain.Dr. Jeffrey Saver, director of theUCLA Comprehensive Stroke Center, was the co-principal investigator of the study, which was conducted at 73 medical centers in 18 countries.“We believe ...
Source: UCLA Newsroom: Health Sciences - May 24, 2019 Category: Universities & Medical Training Source Type: news

Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Acute Ischemic Stroke Therapy Overview.
Abstract The treatment of acute ischemic stroke has undergone dramatic changes recently subsequent to the demonstrated efficacy of intra-arterial (IA) device-based therapy in multiple trials. The selection of patients for both intravenous and IA therapy is based on timely imaging with either computed tomography or magnetic resonance imaging, and if IA therapy is considered noninvasive, angiography with one of these modalities is necessary to document a large-vessel occlusion amenable for intervention. More advanced computed tomography and magnetic resonance imaging studies are available that can be used to identif...
Source: Circulation Research - February 2, 2017 Category: Cardiology Authors: Catanese L, Tarsia J, Fisher M Tags: Circ Res Source Type: research

Effects of Xiaoshuan Enteric-Coated Capsule on White and Gray Matter Injury Evaluated by Diffusion Tensor Imaging in Ischemic Stroke.
This study was to investigate the effects of XSECC on white and gray matter injury in a rat model of ischemic stroke by diffusion tensor imaging (DTI) and histopathological analyses. The ischemia was induced by middle cerebral artery occlusion (MCAO). The cerebral blood flow measured by arterial spin labeling was improved by treatment with XSECC on the 3rd, 7th, 14th and 30th days after MCAO. Spatiotemporal white and gray matter changes in MCAO rats were examined with DTI-derived parameters (fractional anisotropy, FA; apparent diffusion coefficient, ADC; axial diffusivity, λ//; radial diffusivity, λ⊥). The increased FA...
Source: Cell Transplantation - October 4, 2018 Category: Cytology Authors: Zhang J, Chen S, Shi W, Li M, Zhan Y, Yang L, Zou H, Lei J, Chai X, Gao K, Liu J, Wang W, Wang Y, Zhao H Tags: Cell Transplant Source Type: research

Vagus nerve stimulation as a promising adjunctive treatment for ischemic stroke
Publication date: Available online 21 August 2019Source: Neurochemistry InternationalAuthor(s): Jingxi Ma, Peifeng Qiao, Qin Li, Yangyang Wang, Lan Zhang, Liang-Jun Yan, Zhiyou CaiAbstractThe Food and Drug Administration has approved vagus-nerve stimulation (VNS) for the treatment of patients with epilepsy, depression, and headache. By targeting diverse neuroprotective and neuroplasticity pathways, VNS has the potential to be expanded as a treatment for ischemic stroke. VNS has been found to attenuate infarct volume, reduce neurological deficits, and improve memory and cognition in rats with stroke injuries. Some pilot stu...
Source: Neurochemistry International - August 22, 2019 Category: Neuroscience Source Type: research

The Role of Informed Consent for Thrombolysis in Acute Ischemic Stroke.
Authors: Comer AR, Damush TM, Torke AM, Williams LS Abstract Although tissue plasminogen activator (tPA) is the only medication approved by the United States Food and Drug Administration (FDA) for acute ischemic stroke, there is no consensus about the need for informed consent for its use. As a result, hospitals throughout the U.S. have varying requirements regarding obtaining informed consent from patients for the use of tPA, ranging from no requirement for informed consent to a requirement for verbal or written informed consent. We conducted a study to (1) determine current beliefs about obtaining patients' infor...
Source: Journal of Clinical Ethics - December 20, 2019 Category: Medical Ethics Tags: J Clin Ethics Source Type: research

The Clinical Relevance of Serum NDKA, NMDA, PARK7, and UFDP Levels with Phlegm-Heat Syndrome and Treatment Efficacy Evaluation of Traditional Chinese Medicine in Acute Ischemic Stroke.
Authors: Han X, Gao Y, Ma B, Gao Y, Sun Y, Jiang R, Wang Y Abstract According to the methods of Patient-Reported Outcome (PRO) based on the patient reports internationally and referring to U.S. Food and Drug Administration (FDA) guide, some scholars developed this PRO of stroke which is consistent with China's national conditions, and using it the feel of stroke patients was introduced into the clinical efficacy evaluation system of stoke. "Ischemic Stroke TCM Syndrome Factor Diagnostic Scale (ISTSFDS)" and "Ischemic Stroke TCM Syndrome Factor Evaluation Scale (ISTSFES)" were by "Major State Basic Research Developm...
Source: Evidence-based Complementary and Alternative Medicine - November 8, 2015 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research

Medication Adherence and Stroke Prevention: What Real World Data Tells Us.
Authors: Hsieh CY Abstract Medication adherence, by definition,(2) is "the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen." Poor medication adherence can interfere with the ability to treat many diseases, leading to greater complications and a lower quality of life.(3) In this issue of Acta Neurologica Taiwanica, Chen et al.(4) presented the inverse association between adherence of antithrombotic agents and poor outcomes after a first-ever ischemic stroke. The findings were consistent with Sung, et al.(5) that medication nonadherence are prevalent in young adu...
Source: Acta Neurologica Taiwanica - February 7, 2020 Category: Neurology Tags: Acta Neurol Taiwan Source Type: research